Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma

Journal of Thoracic and Cardiovascular Surgery

Volumn 136, Issue 1, 2008, Pages

  Higuchi, Ichirou ^a   Yasuda, Takushi ^a   Yano, Masahiko ^a   Doki, Yuichirou ^a   Miyata, Hiroshi ^a   Tatsumi, Mitsuaki ^a   Fukunaga, Hironori ^a   Takiguchi, Shuji ^a   Fujiwara, Yoshiyuki ^a   Hatazawa, Jun ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEVICE; DRUG UPTAKE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR VOLUME;

EID: 46049107516     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.02.016     Document Type: Article

References (29)

1. Mandard A.M., Dalibard F., Mandard J.C., Marnay J., Henry-Amar M., Petiot J.M., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73 (1994) 2680-2686
2. Yano M., Tsujinaka T., Shiozaki H., Inoue M., Doki Y., Yamamoto M., et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol 70 (1999) 25-32
3. Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., and Hennessy T.P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
4. Kelsen D.P., Ginsberg R., Pajak T.F., Sheahan D.G., Gunderson L., Mortimer J., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339 (1998) 1979-1984
5. Urba S.G., Orringer M.B., Turrisi A., Iannettoni M., Forastiere A., and Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 (2001) 305-313
6. Swisher S.G., Ajani J.A., Komaki R., Nesbitt J.C., Correa A.M., Cox J.D., et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 57 (2003) 120-127
7. Zuccaro Jr. G., Rice T.W., Goldblum J., Medendorp S.V., Becker M., Pimentel R., et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 94 (1999) 906-912
8. Laterza E., de Manzoni G., Guglielmi A., Rodella L., Tedesco P., and Cordiano C. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg 67 (1999) 1466-1469
9. Griffith J.F., Chan A.C., Chow L.T., Leung S.F., Lam Y.H., Liang E.Y., et al. Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT. Br J Radiol 72 (1999) 678-684
10. Jones D.R., Parker Jr. L.A., Detterbeck F.C., and Egan T.M. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85 (1999) 1026-1032
11. Brücher B.L., Weber W., Bauer M., Fink U., Avril N., Stein H.J., et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233 (2001) 300-309
12. Weber W.A., Ott K., Becker K., Dittler H.J., Helmberger H., Avril N.E., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
13. Flamen P., Van Cutsem E., Lerut A., Cambier J.P., Haustermans K., Bormans G., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 (2002) 361-368
14. Kato H., Kuwano H., Nakajima M., Miyazaki T., Yoshikawa M., Masuda N., et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184 (2002) 279-283
15. 18F]fluoro-d-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 4 (2002) 301-310
16. 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21 (2003) 428-432
17. 18F]-fluoro-d-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol 5 (2003) 337-346
18. Wieder H.A., Brücher B.L., Zimmermann F., Becker K., Lordick F., Beer A., et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22 (2004) 900-908
19. Song S.Y., Kim J.H., Ryu J.S., Lee G.H., Kim S.B., Park S.I., et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1053-1059
20. Westerterp M., Omloo J.M., Sloof G.W., Hulshof M.C., Hoekstra O.S., Crezee H., et al. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Int J Hyperthermia 22 (2006) 149-160
21. 18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 243 (2006) 472-478
22. 18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 95 (2006) 1174-1179
23. Swisher S.G., Erasmus J., Maish M., Correa A.M., Macapinlac H., Ajani J.A., et al. 2-fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101 (2004) 1776-1785
24. Duong C.P., Hicks R.J., Weih L., Drummond E., Leong T., Michael M., et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging 33 (2006) 770-778
25. 18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer. Nucl Med Commun 24 (2003) 963-970
26. Tatsumi M., Yutani K., Watanabe Y., Miyoshi S., Tomiyama N., Johkoh T., et al. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med 40 (1999) 566-573
27. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in local recurrence of rectal cancer. Int J Oncol 20 (2002) 691-695
28. Shiozaki H., Yano M., Tsujinaka T., Inoue M., Tamura S., Doki Y., et al. Lymph node metastasis along the recurrent nerve chain is an indication for cervical lymph node dissection in thoracic esophageal cancer. Dis Esophagus 14 (2001) 191-196
29. Japanese Society for Esophageal Diseases. Guidelines for the clinical and pathological studies on carcinoma of the esophagus. 9th ed. (1999), Kanehara, Tokyo